FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783143299> ?p ?o ?g. }

• W2783143299 endingPage "180" @default.
• W2783143299 startingPage "180" @default.
• W2783143299 abstract "Omega-6 polyunsaturated fatty acid (n-6 PUFA) is the predominant polyunsaturated fatty acid (PUFA), especially in Western diet. A high omega-6/omega-3 ratio in Western diets is implicated in the development of cardiovascular diseases and inflammatory processes. Studies in animal models and in humans have demonstrated beneficial effects of omega-3 PUFA (n-3 PUFA) in a variety of diseases, including cardiac arrhythmias and inflammatory diseases, as well as breast and colon cancer. The molecular mechanisms underlying the effects of n-3 PUFA are still not well understood. Possible mechanisms include competition between n-3 and n-6 PUFAs at the cyclooxygenase (COX) and lipoxygenase (LOX) and cytochrome P450 levels, and subsequent formation of oxylipins with specific anti-inflammatory or anti-arrhythmic effects. In this study, we report the impact of routine long-term treatment with prescription-grade n-3 PUFA (either 840 mg or 1680 mg per day) on blood cell membrane fatty acid composition, as well as plasma oxylipin patterns, in a patient population with severe hyperlipidemia and cardiovascular disease who are on standard lipid-lowering and cardioprotective medications. Lipidomics analyses were performed by LC/ESI-MS/MS. Supplementation led to a dose-dependent increase in n-3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the blood cell fraction. We also observed a dose-dependent increase in EPA- and DHA-derived epoxy metabolites, whereas the effect of n-3 PUFA supplementation on LOX-dependent EPA- and DHA-derived hydroxy metabolites was less pronounced, with a tendency towards lower metabolites in subjects with higher n-3 PUFA levels. These data thus generally confirm effects of n-3 PUFA supplementation observed previously in healthy individuals. Additionally, they indicate a suppressive effect of high n-3 PUFA supplementation on the formation of LOX metabolites in the context of concomitant aspirin medication." @default.
• W2783143299 created "2018-01-26" @default.
• W2783143299 creator A5006108443 @default.
• W2783143299 creator A5021934186 @default.
• W2783143299 creator A5034702347 @default.
• W2783143299 creator A5038326968 @default.
• W2783143299 creator A5039908242 @default.
• W2783143299 creator A5062066440 @default.
• W2783143299 creator A5071942582 @default.
• W2783143299 creator A5088300809 @default.
• W2783143299 date "2018-01-08" @default.
• W2783143299 modified "2023-10-01" @default.
• W2783143299 title "Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting" @default.
• W2783143299 cites W1828408380 @default.
• W2783143299 cites W1971091197 @default.
• W2783143299 cites W1971999946 @default.
• W2783143299 cites W1972484742 @default.
• W2783143299 cites W1986510231 @default.
• W2783143299 cites W2001954239 @default.
• W2783143299 cites W2006574739 @default.
• W2783143299 cites W2008210766 @default.
• W2783143299 cites W2032147202 @default.
• W2783143299 cites W2034961474 @default.
• W2783143299 cites W2038222125 @default.
• W2783143299 cites W2066116031 @default.
• W2783143299 cites W2080621715 @default.
• W2783143299 cites W2085149062 @default.
• W2783143299 cites W2086010033 @default.
• W2783143299 cites W2100851898 @default.
• W2783143299 cites W2103018276 @default.
• W2783143299 cites W2104285446 @default.
• W2783143299 cites W2105806768 @default.
• W2783143299 cites W2108418875 @default.
• W2783143299 cites W2111416524 @default.
• W2783143299 cites W2112873650 @default.
• W2783143299 cites W2121573818 @default.
• W2783143299 cites W2125555008 @default.
• W2783143299 cites W2139086060 @default.
• W2783143299 cites W2140309790 @default.
• W2783143299 cites W2140950206 @default.
• W2783143299 cites W2141885792 @default.
• W2783143299 cites W2148818926 @default.
• W2783143299 cites W2160768664 @default.
• W2783143299 cites W2162465757 @default.
• W2783143299 cites W2300160750 @default.
• W2783143299 cites W2479517385 @default.
• W2783143299 cites W2530522598 @default.
• W2783143299 cites W2550751504 @default.
• W2783143299 cites W2597054569 @default.
• W2783143299 cites W2624982586 @default.
• W2783143299 cites W4241413696 @default.
• W2783143299 doi "https://doi.org/10.3390/ijms19010180" @default.
• W2783143299 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5796129" @default.
• W2783143299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29316682" @default.
• W2783143299 hasPublicationYear "2018" @default.
• W2783143299 type Work @default.
• W2783143299 sameAs 2783143299 @default.
• W2783143299 citedByCount "22" @default.
• W2783143299 countsByYear W27831432992018 @default.
• W2783143299 countsByYear W27831432992019 @default.
• W2783143299 countsByYear W27831432992020 @default.
• W2783143299 countsByYear W27831432992021 @default.
• W2783143299 countsByYear W27831432992022 @default.
• W2783143299 countsByYear W27831432992023 @default.
• W2783143299 crossrefType "journal-article" @default.
• W2783143299 hasAuthorship W2783143299A5006108443 @default.
• W2783143299 hasAuthorship W2783143299A5021934186 @default.
• W2783143299 hasAuthorship W2783143299A5034702347 @default.
• W2783143299 hasAuthorship W2783143299A5038326968 @default.
• W2783143299 hasAuthorship W2783143299A5039908242 @default.
• W2783143299 hasAuthorship W2783143299A5062066440 @default.
• W2783143299 hasAuthorship W2783143299A5071942582 @default.
• W2783143299 hasAuthorship W2783143299A5088300809 @default.
• W2783143299 hasBestOaLocation W27831432991 @default.
• W2783143299 hasConcept C115368759 @default.
• W2783143299 hasConcept C181199279 @default.
• W2783143299 hasConcept C185592680 @default.
• W2783143299 hasConcept C19038510 @default.
• W2783143299 hasConcept C2776091944 @default.
• W2783143299 hasConcept C2777171753 @default.
• W2783143299 hasConcept C2778078955 @default.
• W2783143299 hasConcept C2779943694 @default.
• W2783143299 hasConcept C3017514745 @default.
• W2783143299 hasConcept C3946865 @default.
• W2783143299 hasConcept C526171541 @default.
• W2783143299 hasConcept C543025807 @default.
• W2783143299 hasConcept C55493867 @default.
• W2783143299 hasConcept C62231903 @default.
• W2783143299 hasConcept C71924100 @default.
• W2783143299 hasConcept C86803240 @default.
• W2783143299 hasConcept C98274493 @default.
• W2783143299 hasConceptScore W2783143299C115368759 @default.
• W2783143299 hasConceptScore W2783143299C181199279 @default.
• W2783143299 hasConceptScore W2783143299C185592680 @default.
• W2783143299 hasConceptScore W2783143299C19038510 @default.
• W2783143299 hasConceptScore W2783143299C2776091944 @default.
• W2783143299 hasConceptScore W2783143299C2777171753 @default.
• W2783143299 hasConceptScore W2783143299C2778078955 @default.

• next